Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Published:2022-04-06 Issue:10 Volume:49 Page:3581-3592
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Lawal Ismaheel O.^ORCID,Morgenstern Alfred,Vorster Mariza,Knoesen Otto,Mahapane Johncy,Hlongwa Khanyisile N.,Maserumule Letjie C.,Ndlovu Honest,Reed Janet D.,Popoola Gbenga O.,Mokoala Kgomotso M. G.,Mdlophane Amanda,Bruchertseifer Frank,Sathekge Mike M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-05778-w.pdf

Reference43 articles.

1. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body 68Ga-PSMA-11 PET/CT for bone metastases detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61:405–11.

2. James ND, Spears M, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.

3. Kesler M, Kerzhner K, Druckmann I, Kuten J, Levine C, Sarid D, et al. Staging 68Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. Eur J Nucl Med Mol Imaging. Epub ahead of print on 27 December 2021.

4. Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015;23:237–47.

5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer;Cancers;2024-08-31

2. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

3. Advances in PSMA Alpha Theragnostics;Seminars in Nuclear Medicine;2024-07

4. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals;PET Clinics;2024-07

5. Deescalated²²⁵Ac-PSMA-617 Versus¹⁷⁷Lu/²²⁵Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients;Journal of Nuclear Medicine;2024-06-06